IRCT20191230045950N2 IRCT 2022-04-10 Shahid Beheshti University of Medical Sciences Ivabradine effect on ventricular rate in non-paroxysmal atrial fibrillation patients Comparison of Ivabradine effect versus placebo on ventricular rate in patients with non-paroxysmal atrial fibrillation under standard medical treatment 2022-02-20 anticipated 100 Complete https://irct.ir/trial/62170 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The simple randomization method will be done via random number table ،individually, and each patient have her/his own code. The first 50 extracted numbers from 100, (for example numbers 19, 07,02, and 20, …) , will be placed in the drug receiving group, and the rest, (for example, 01,03,05,06,13 , …) in the placebo group. Then, by referring to the clinic, patients who are eligible for trial will be assessed in the order of entry number based on the framework specified in the target groups, Blinding description: Patients do not know whether they have received medication or a placebo Researchers, outcome assessors, and statistical analyzers are not aware of which patients received the Ivabradine or placebo. . 3 Atrial fibrilation. Intervention 1: Intervention group: Patients in this group are prescribed Ivabradine at a dose of 5 mg twice a day (manufactured by Kobel Daroo Company) for one month.24 hours ambulatory heart rhythm monitoring is performed before and after one month of treatment. Intervention 2: Control group: Patients in this group receive a placebo twice a day for one month.24 hours ambulatory heart rhythm monitoring is performed before and one month after receiving the placebo. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.